Zacks Investment Research
09 Jan 2026, 15:41 UTC · 39w ago
Impact · against what's priced in
The article provides mildly positive momentum indicators for ALLO and ANTX, specifically through Zacks Rank upgrades and earnings estimate revisions. However, as these are lagging indicators based on existing analyst trends, the immediate catalyst potential is limited.
No priced-in read yet
What the story claims
4 claims · scored −1 bearish … +1 bullish
Allogene Therapeutics (ALLO) currently holds a Zacks Rank of #2 (Buy).
More positive than 79% of claims this week
The Zacks Consensus Estimate for Allogene Therapeutics' full-year earnings has increased by 3% over the past quarter.
Continue reading
5 related stories
A Zacks Rank of #2 and a 3% increase in full-year earnings estimates suggest improving analyst sentiment and short-term price momentum.
Read from the article alone
No priced-in read yet
The company's Zacks Rank of #2 and a 5.2% increase in consensus EPS estimates over three months signal a bullish short-term outlook.
Read from the article alone
Scored by the NIS engine · methodology.
More positive than 66% of claims this week
AN2 Therapeutics (ANTX) also holds a Zacks Rank of #2 (Buy) and has seen a 5.2% increase in consensus EPS estimates over the last three months.
More positive than 66% of claims this week
Allogene Therapeutics is outperforming the broader Medical sector (8.8% YTD vs 7.8% average) but underperforming its specific Biomedical and Genetics industry (19.1% average).
More positive than 45% of claims this week
Which stocks this story touches
More positive than 83% of ticker scores this week
The company has a Zacks Rank of #2 (Buy), increasing EPS estimates, and significant year-to-date outperformance.
More positive than 77% of ticker scores this week
The company has a Zacks Rank of #2 (Buy), improving earnings estimates, and is outperforming its sector.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
53m ago
+222.0%
Price agrees with the score
$4.25 vs $1.32 close before publication (Jan 8) · not market-adjusted
ANTX chart →−4.7%
Price is moving against the score
$1.42 vs $1.49 close before publication (Jan 8) · not market-adjusted
ALLO chart →
